Advanced
  Home Compare Reports

Comparison with Similar Reports

Cancer Biomarkers Market by Type (Protein, Genetic), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Profiling Technology (Omics, Imaging, Immu...

Publisher:        MarketsandMarkets

# of Pages:        278

Rating: 

1 User License $7,150

Publication Date:  March, 2022

Price:       $7,150 / User License




1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.2.2 MARKETS COVERED 37
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION 37
1.2.3 YEARS CONSIDERED FOR THE STUDY 38
1.3 CURRENCY 38
1.4 LIMITATIONS 38
1.5 STAKEHOLDERS 39
1.6 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.2 RESEARCH APPROACH 41
FIGURE 2 CANCER BIOMARKERS MARKET: RESEARCH DESIGN 41
2.2.1 SECONDARY DATA 42
2.2.1.1 Key data from secondary sources 42
2.2.2 PRIMARY DATA 43
2.2.2.1 Primary sources 44
2.2.2.2 Key data from primary sources 44
2.2.2.3 Key industry insights 45
2.2.2.4 Breakdown of primary interviews 46
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND
DEMAND SIDE PARTICIPANTS 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 46
2.3 MARKET SIZE ESTIMATION 47
2.3.1 BOTTOM-UP APPROACH 47
2.3.1.1 Approach 1: Company revenue estimation approach 48
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 48
2.3.1.2 Approach 2: Presentations of companies and primary interviews 48
2.3.1.3 Growth forecast 49
2.3.1.4 CAGR projections 49
FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 49
2.3.2 TOP-DOWN APPROACH 50
FIGURE 7 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH 50
 
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 51
FIGURE 8 DATA TRIANGULATION METHODOLOGY 51
2.5 MARKET SHARE 52
2.6 ASSUMPTIONS FOR THE STUDY 52
2.7 LIMITATIONS 53
2.8 RISK ASSESSMENT 53
2.8.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET 53
2.9 GROWTH RATE ASSUMPTIONS 54
2.10 COVID-19 HEALTH ASSESSMENT 54
2.11 COVID-19 ECONOMIC ASSESSMENT 54
2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO 54
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 55
FIGURE 10 RECOVERY SCENARIO OF GLOBAL ECONOMY 56
2.13 ASSESSMENT OF IMPACT OF COVID-19 ON CANCER BIOMARKERS MARKET 57
3 EXECUTIVE SUMMARY 58
FIGURE 11 CANCER BIOMARKERS MARKET, BY BIOMARKERS TYPE,
2021 VS. 2026 (USD MILLION) 58
FIGURE 12 CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2021 VS. 2026 (USD MILLION) 59
FIGURE 13 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 60
FIGURE 14 CANCER BIOMARKERS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 60
FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 61
4 PREMIUM INSIGHTS 62
4.1 CANCER BIOMARKERS MARKET OVERVIEW 62
FIGURE 16 RISING TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF CANCER BIOMARKERS TO DRIVE MARKET GROWTH 62
4.2 CANCER BIOMARKERS MARKET SHARE, BY BIOMARKER TYPE, 2021 VS. 2026 63
FIGURE 17 THE PROTEIN BIOMARKERS SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 63
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2021 VS. 2026 63
FIGURE 18 LUNG CANCER SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 63
4.4 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2021 VS. 2026 64
FIGURE 19 THE OMICS TECHNOLOGIES SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 64
4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2021 VS. 2026 64
FIGURE 20 HOSPITALS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 64
4.6 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65
FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE
DURING FORECAST PERIOD 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 67
FIGURE 22 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 67
5.2.1 DRIVERS 67
5.2.1.1 Rising technological advancements in the development of cancer biomarkers 67
5.2.1.2 Increasing incidence of cancer worldwide 68
TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION) 68
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015─2O35 69
5.2.1.3 Increasing use of cancer biomarkers in drug discovery & development 69
5.2.1.4 Increasing R&D on cancer biomarkers 70
5.2.2 RESTRAINTS 70
5.2.2.1 Technical issues related to sample collection and storage 70
5.2.2.2 High capital investments and extensive timelines for the development of cancer biomarkers 71
TABLE 3 TIMEFRAME FOR THE DEVELOPMENT OF BIOMARKERS 71
5.2.2.3 Unfavorable regulatory and reimbursement scenario 71
5.2.3 OPPORTUNITIES 72
5.2.3.1 Increased recognition of personalized medicine 72
FIGURE 23 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS 73
5.2.3.2 Growing application areas of companion diagnostics 73
5.2.3.3 Emerging economies 73
5.2.4 CHALLENGES 74
5.2.4.1 Challenges associated with cancer biomarker validation 74
5.2.4.2 Shortage of skilled professionals 74
5.3 IMPACT OF COVID-19 ON CANCER BIOMARKERS MARKET 75
5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS 77
5.4.1 CANCER BIOMARKERS MARKET 77
FIGURE 24 PESSIMISTIC SCENARIO 77
FIGURE 25 OPTIMISTIC SCENARIO 77
FIGURE 26 REALISTIC SCENARIO 78
5.5 PRICING ANALYSIS 79
TABLE 4 PRICE OF CANCER BIOMARKERS BY PRODUCT & SERVICE (2021) 79
5.6 PATENT ANALYSIS 80
5.6.1 PATENT ANALYSIS OF THE CANCER BIOMARKERS MARKET 80
5.7 TRADE ANALYSIS 81
5.7.1 TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS 81
 
TABLE 5 IMPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016–2020 (USD MILLION) 81
TABLE 6 EXPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016–2020 (USD MILLION) 81
5.8 VALUE CHAIN ANALYSIS 82
FIGURE 27 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE 82
5.9 SUPPLY CHAIN ANALYSIS 83
FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 83
5.10 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET 84
FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 84
5.10.1 ROLE IN ECOSYSTEM 84
5.11 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 7 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.11.1 THREAT OF NEW ENTRANTS 85
5.11.2 THREAT OF SUBSTITUTES: 85
5.11.3 BARGAINING POWER OF BUYERS 85
5.11.4 BARGAINING POWER OF SUPPLIERS 85
5.11.5 DEGREE OF COMPETITION 86
5.12 REGULATORY ANALYSIS 86
5.12.1 INTRODUCTION 86
5.12.2 CANCER BIOMARKERS QUALIFICATION IN THE US 86
5.12.3 CANCER BIOMARKERS QUALIFICATION IN THE EU 86
5.12.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN THE EU AND THE US 87
5.12.5 METHOD: EMA APPROVALS 87
5.12.6 METHOD: FDA APPROVALS 88
5.13 TECHNOLOGY ANALYSIS 88
5.14 PESTLE ANALYSIS 91
5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS 92
5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC 92
FIGURE 30 YC-YCC SHIFT FOR CANCER BIOMARKERS MARKET 92
6 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE 93
6.1 INTRODUCTION 94
TABLE 8 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 94
TABLE 9 CANCER BIOMARKERS MARKET FOR BIOMARKERS TYPE,
BY REGION, 2020–2026 (USD MILLION) 94
6.2 PROTEIN BIOMARKERS 95
6.2.1 INCREASED EFFORTS OF PHARMACEUTICAL COMPANIES TO DISCOVER PROTEIN BIOMARKERS FOR EARLY STAGES TO DRIVE MARKET GROWTH 95
TABLE 10 CANCER BIOMARKERS MARKET FOR PROTEIN BIOMARKERS, BY REGION, 2020–2026 (USD MILLION) 95
 
6.3 GENETIC BIOMARKERS 96
6.3.1 ADVANCEMENTS IN HIGH-THROUGHPUT TECHNOLOGIES TO
DRIVE MARKET GROWTH 96
TABLE 11 CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS,
BY TYPE, 2020–2026 (USD MILLION) 96
TABLE 12 CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS,
BY REGION, 2020–2026 (USD MILLION) 97
6.3.2 LUNG CANCER 97
6.3.3 BREAST CANCER 99
6.3.4 PROSTATE CANCER 99
6.3.5 LEUKEMIA 100
6.3.6 OTHER CANCERS 101
6.4 OTHER CANCER BIOMARKERS 102
TABLE 13 CANCER BIOMARKERS MARKET FOR OTHER CANCER BIOMARKERS,
BY REGION, 2020–2026 (USD MILLION) 102
7 CANCER BIOMARKERS MARKET, BY CANCER TYPE 103
7.1 INTRODUCTION 104
TABLE 14 CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 104
TABLE 15 CANCER BIOMARKERS MARKET FOR CANCER TYPE, BY REGION,
2020–2026 (USD MILLION) 105
7.2 BREAST CANCER 105
7.2.1 AVAILABILITY & UTILISATION OF ADVANCED TECHNOLOGIES BY MAJOR PLAYERS IN BREAST CANCER DETECTION TO DRIVE MARKET GROWTH 105
TABLE 16 BREAST CANCER INCIDENCE, BY REGION, 2020 VS 2040 106
TABLE 17 CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY REGION,
2020–2026 (USD MILLION) 106
7.3 LUNG CANCER 106
7.3.1 INCREASING FOCUS ON LUNG CANCER BIOMARKERS DEVELOPMENT TO DRIVE MARKET GROWTH 106
TABLE 18 LUNG CANCER INCIDENCE, BY REGION, 2020 VS 2040 107
TABLE 19 CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY REGION,
2020–2026 (USD MILLION) 107
7.4 COLORECTAL CANCER (CRC) 108
7.4.1 RISING DEMAND FOR BIOMARKERS IN THE EARLY DIAGNOSIS &
PROGNOSIS OF CRC TO DRIVE THE MARKET GROWTH 108
TABLE 20 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS 2040 108
TABLE 21 CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2026 (USD MILLION) 108
7.5 PROSTATE CANCER 109
7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES ARE ENABLING THE DEVELOPMENT OF NEW BIOMARKERS FOR PROSTATE CANCER 109
TABLE 22 CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2020–2026 (USD MILLION) 109
 
7.6 MELANOMA 110
7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE THE MARKET GROWTH 110
TABLE 23 MELANOMA INCIDENCE, BY REGION, 2020 VS 2040 110
TABLE 24 CANCER BIOMARKERS MARKET FOR MELANOMA, BY REGION,
2020–2026 (USD MILLION) 111
7.7 LEUKEMIA 111
7.7.1 RESEARCH STUDIES FOR THE DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS IN LEUKEMIA TO DRIVE MARKET GROWTH 111
TABLE 25 CANCER BIOMARKERS MARKET FOR LEUKEMIA, BY REGION,
2020–2026 (USD MILLION) 112
7.8 THYROID CANCER 112
7.8.1 RESEARCH UNDERTAKEN FOR THE IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO DRIVE THE MARKET GROWTH 112
TABLE 26 CANCER BIOMARKERS MARKET FOR THYROID CANCER, BY REGION,
2020–2026 (USD MILLION) 113
7.9 BLADDER CANCER 113
7.9.1 APPROVAL OF SEVERAL URINARY BIOMARKERS FOR THE DETECTION OF BLADDER CANCER TO SUPPORT THE SEGMENT GROWTH 113
TABLE 27 CANCER BIOMARKERS MARKET FOR BLADDER CANCER, BY REGION,
2020–2026 (USD MILLION) 114
7.10 NON-HODGKIN’S LYMPHOMA (NHL) 114
7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE THE MARKET GROWTH 114
TABLE 28 CANCER BIOMARKERS MARKET FOR NON-HODGKIN’S LYMPHOMA,
BY REGION, 2020–2026 (USD MILLION) 115
7.11 KIDNEY CANCER 115
7.11.1 DEVELOPMENT OF SEVERAL NEW TARGETED THERAPIES FOR THE TREATMENT OF KIDNEY CANCER TO DRIVE THE MARKET GROWTH 115
TABLE 29 CANCER BIOMARKERS MARKET FOR KIDNEY CANCER, BY REGION,
2020–2026 (USD MILLION) 116
7.12 OTHER CANCERS 116
TABLE 30 CANCER BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION,
2020–2026 (USD MILLION) 117
8 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY 118
8.1 INTRODUCTION 119
TABLE 31 CANCER BIOMARKERS MARKET FOR PROFILING TECHNOLOGY, BY TYPE, 2020–2026 (USD MILLION) 119
TABLE 32 CANCER BIOMARKERS MARKET FOR PROFILING TECHNOLOGY, BY REGION, 2020–2026 (USD MILLION) 119
8.2 OMICS TECHNOLOGY 120
8.2.1 INCREASING DEMAND FOR ADVANCED OMICS TECHNOLOGIES TO DRIVE MARKET GROWTH 120
TABLE 33 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGY, BY TYPE,
2020–2026 (USD MILLION) 120
TABLE 34 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGY, BY REGION, 2020–2026 (USD MILLION) 121
8.2.2 PROTEOMICS 121
8.2.2.1 Increasing discovery rate of protein biomarkers and the rising need for rapid and cost-efficient diagnostic tests to drive segment growth 121
TABLE 35 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION,
2020–2026 (USD MILLION) 122
8.2.3 GENOMICS 122
8.2.3.1 The rising potential of genomics technologies in the development of biomarkers for disease prediction 122
TABLE 36 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2020–2026 (USD MILLION) 123
TABLE 37 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION,
2020–2026 (USD MILLION) 123
8.2.3.2 NEXT-GENERATION SEQUENCING (NGS) 124
8.2.3.2.1 Introducing advanced NGS platforms by leading players to increase productivity to drive the growth of this segment 124
TABLE 38 CANCER BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY REGION, 2020–2026 (USD MILLION) 124
8.2.3.3 POLYMERASE CHAIN REACTION (PCR) 125
8.2.3.3.1 Cost-effectiveness and the easy availability of PCR tests to propel the growth of this segment 125
TABLE 39 CANCER BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2020–2026 (USD MILLION) 126
8.2.4 OTHER OMICS TECHNOLOGIES 126
TABLE 40 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES,
BY REGION, 2020–2026 (USD MILLION) 127
8.3 IMAGING TECHNOLOGIES 127
8.3.1 THE USE OF IMAGING BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT PROCESSES TO DRIVE THE GROWTH OF THIS MARKET 127
TABLE 41 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2020–2026 (USD MILLION) 128
TABLE 42 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2020–2026 (USD MILLION) 128
8.3.2 ULTRASOUND IMAGING 128
8.3.2.1 Use of ultrasound for biomarker research in the understanding of disease onset & progression to drive the growth of this segment 128
TABLE 43 CANCER BIOMARKERS MARKET FOR ULTRASOUND IMAGING, BY REGION, 2020–2026 (USD MILLION) 129
8.3.3 COMPUTED TOMOGRAPHY (CT) 129
8.3.3.1 The adoption of CT in cancer biomarker discovery is
increasing rapidly 129
TABLE 44 CANCER BIOMARKERS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2020–2026 (USD MILLION) 130
8.3.4 MAGNETIC RESONANCE IMAGING (MRI) 130
8.3.4.1 MRI use in differentiating normal and diseased tissues to pinpoint cancerous cells precisely supports the growth of this segment 130
TABLE 45 CANCER BIOMARKERS MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2020–2026 (USD MILLION) 131
8.3.5 POSITRON EMISSION TOMOGRAPHY (PET) 131
8.3.5.1 Development of lab-on-chip-based multiplex assays to support the market growth 131
TABLE 46 CANCER BIOMARKERS MARKET FOR POSITRON EMISSION TOMOGRAPHY,
BY REGION, 2020–2026 (USD MILLION) 132
8.3.6 MAMMOGRAPHY 132
8.3.6.1 Advanced technologies like 3D mammography to drive the growth of this segment 132
TABLE 47 CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY REGION,
2020–2026 (USD MILLION) 133
8.4 IMMUNOASSAYS 133
8.4.1 THE INCREASING PREVALENCE OF BREAST CANCER IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT 133
TABLE 48 CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION,
2020–2026 (USD MILLION) 135
8.5 BIOINFORMATICS 135
8.5.1 RISING TECHNOLOGICAL ADVANCEMENTS AND THE GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET GROWTH 135
TABLE 49 CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY REGION,
2020–2026 (USD MILLION) 136
8.6 CYTOGENETICS 136
8.6.1 CYTOGENETICS ARE GENETICS-BASED TESTS THAT ARE RELIABLE IN THE QUANTITATIVE & QUALITATIVE EVALUATION OF BIOMARKERS 136
TABLE 50 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY TYPE,
2020–2026 A(USD MILLION) 137
TABLE 51 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY REGION,
2020–2026 (USD MILLION) 137
8.6.2 IN-SITU HYBRIDIZATION (ISH) 137
8.6.2.1 Use of ISH-based diagnostic tests help identify specific biomarkers in clinical trials 137
TABLE 52 CANCER BIOMARKERS MARKET FOR IN-SITU HYBRIDIZATION, BY REGION, 2020–2026 (USD MILLION) 138
8.6.3 OTHER CYTOGENETICS-BASED TESTS 138
TABLE 53 CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY REGION, 2020–2026 (USD MILLION) 139
9 CANCER BIOMARKERS MARKET, BY APPLICATION 140
9.1 INTRODUCTION 141
TABLE 54 CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 141
TABLE 55 CANCER BIOMARKERS MARKET FOR APPLICATION, BY REGION,
2020–2026 (USD MILLION) 141
9.2 DIAGNOSTICS 142
9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO DRIVE MARKET GROWTH 142
TABLE 56 CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION,
2020–2026 (USD MILLION) 142
 
9.3 RESEARCH & DEVELOPMENT 143
9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON BIOMARKERS USE IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET GROWTH 143
TABLE 57 CANCER BIOMARKERS MARKET FOR RESEARCH & DEVELOPMENT,
BY REGION, 2020–2026 (USD MILLION) 143
9.4 PROGNOSTICS 144
9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO DRIVE MARKET GROWTH 144
TABLE 58 CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY REGION,
2020–2026 (USD MILLION) 144
9.5 RISK ASSESSMENT 144
9.5.1 RISK ASSESSMENT BIOMARKERS TO INCREASE CANCER CLINICAL TRIALS FOR DRUG DEVELOPMENT 144
TABLE 59 CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION,
2020–2026 (USD MILLION) 145
9.6 OTHER APPLICATIONS 145
TABLE 60 CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2026 (USD MILLION) 146
10 CANCER BIOMARKERS MARKET, BY REGION 147
10.1 INTRODUCTION 148
TABLE 61 CANCER BIOMARKERS MARKET, BY REGION, 2020–2026 (USD MILLION) 148
10.2 NORTH AMERICA 149
TABLE 62 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020,
BY CANCER TYPE 149
FIGURE 31 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 150
FIGURE 32 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT 150
TABLE 63 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 151
TABLE 64 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 151
TABLE 65 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION) 152
TABLE 66 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 152
TABLE 67 NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 152
TABLE 68 NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 153
TABLE 69 NORTH AMERICA: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 153
TABLE 70 NORTH AMERICA: CYTOGENETICS MARKET, BY TYPE,
2020–2026 (USD MILLION) 153
TABLE 71 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 154
 
10.2.1.1 Increasing use of cancer biomarkers for cancer treatment drives the market growth 154
TABLE 72 KEY GROWTH STRATEGIES BY LEADING PLAYER FOR THE DEVELOPMENT
OF CANCER BIOMARKERS 155
TABLE 73 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 156
TABLE 74 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 156
TABLE 75 US: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 157
TABLE 76 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 157
TABLE 77 US: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 157
TABLE 78 US: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 158
TABLE 79 US: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 158
TABLE 80 US: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 158
TABLE 81 US: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 159
10.2.2 CANADA 159
10.2.2.1 Increasing government initiatives for the discovery & development of cancer biomarkers to drive the market growth 159
TABLE 82 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 160
TABLE 83 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 161
TABLE 84 CANADA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 161
TABLE 85 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 162
TABLE 86 CANADA: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 162
TABLE 87 CANADA: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 162
TABLE 88 CANADA: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 163
TABLE 89 CANADA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 163
TABLE 90 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 163
10.3 EUROPE 164
FIGURE 33 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 165
TABLE 91 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 165
TABLE 92 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 166
TABLE 93 EUROPE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 166
TABLE 94 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY , 2020–2026 (USD MILLION) 167
TABLE 95 EUROPE: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 167
TABLE 96 EUROPE: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 167
TABLE 97 EUROPE: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 168
TABLE 98 EUROPE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 168
TABLE 99 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 168
10.3.1 GERMANY 169
10.3.1.1 Favorable government health policies to drive the market growth for cancer biomarkers in Germany 169
TABLE 100 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 169
TABLE 101 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 170
TABLE 102 GERMANY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 170
TABLE 103 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 171
TABLE 104 GERMANY: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 171
TABLE 105 GERMANY: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 171
TABLE 106 GERMANY: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 172
TABLE 107 GERMANY: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 172
TABLE 108 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 172
10.3.2 UK 173
10.3.2.1 Availability of government funding and strategic collaborations with biotech firms have significantly boosted the adoption of biomarkers in the UK 173
TABLE 109 UK: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 173
TABLE 110 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 174
TABLE 111 UK: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 174
TABLE 112 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY ,
2020–2026 (USD MILLION) 175
TABLE 113 UK: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 175
TABLE 114 UK: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 175
TABLE 115 UK: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 176
TABLE 116 UK: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 176
TABLE 117 UK: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 176
10.3.3 FRANCE 177
10.3.3.1 Increasing government investments in genomics & proteomics research to drive the market growth in France 177
TABLE 118 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 177
TABLE 119 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 178
TABLE 120 FRANCE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 178
TABLE 121 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 179
TABLE 122 FRANCE: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 179
TABLE 123 FRANCE: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 179
TABLE 124 FRANCE: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 180
TABLE 125 FRANCE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 180
TABLE 126 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 180
10.3.4 ITALY 181
10.3.4.1 Increasing research activities on the discovery for novel cancer biomarkers using tissue diagnostic techniques to drive the market growth 181
TABLE 127 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 182
TABLE 128 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 182
TABLE 129 ITALY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 183
TABLE 130 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 183
TABLE 131 ITALY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 183
TABLE 132 ITALY: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 184
TABLE 133 ITALY: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 184
TABLE 134 ITALY: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 184
TABLE 135 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 185
10.3.5 SPAIN 185
10.3.5.1 Increasing focus on personalized medicine to drive the market growth for cancer biomarkers in Spain 185
TABLE 136 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 186
TABLE 137 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 186
TABLE 138 SPAIN: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 187
TABLE 139 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 187
TABLE 140 SPAIN: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 187
TABLE 141 SPAIN: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 188
TABLE 142 SPAIN: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 188
TABLE 143 SPAIN: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 188
TABLE 144 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 189
10.3.6 REST OF EUROPE 189
TABLE 145 ROE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 190
TABLE 146 ROE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 190
TABLE 147 ROE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 191
TABLE 148 ROE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 191
TABLE 149 ROE: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 191
TABLE 150 ROE: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 192
TABLE 151 ROE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 192
TABLE 152 ROE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 192
FIGURE 34 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 193
FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT 194
TABLE 153 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY COUNTRY,
2020–2026 (USD MILLION) 195
TABLE 154 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 195
TABLE 155 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 196
TABLE 156 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 196
TABLE 157 ASIA PACIFIC: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 196
TABLE 158 ASIA PACIFIC: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 197
TABLE 159 ASIA PACIFIC: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 197
TABLE 160 ASIA PACIFIC: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 197
TABLE 161 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 198
10.3.7 CHINA 198
10.3.7.1 Increasing burden of diseases and growing focus on novel drugs development to drive demand for cancer biomarkers 198
TABLE 162 CHINA: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040 199
TABLE 163 CHINA: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 199
TABLE 164 CHINA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 200
TABLE 165 CHINA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 200
TABLE 166 CHINA: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 200
TABLE 167 CHINA: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 201
TABLE 168 CHINA: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 201
TABLE 169 CHINA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 201
TABLE 170 CHINA: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 202
10.3.8 JAPAN 202
10.3.8.1 Strategic collaborations with leading pharmaceutical companies to drive market growth 202
TABLE 171 JAPAN: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040 203
TABLE 172 JAPAN: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 204
TABLE 173 JAPAN: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 204
TABLE 174 JAPAN: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 205
TABLE 175 JAPAN: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 205
TABLE 176 JAPAN: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 205
TABLE 177 JAPAN: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 206
TABLE 178 JAPAN: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 206
TABLE 179 JAPAN: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 206
10.3.9 INDIA 207
10.3.9.1 Increased demand for early cancer diagnosis to support market growth 207
TABLE 180 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 208
TABLE 181 INDIA: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 208
TABLE 182 INDIA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 209
TABLE 183 INDIA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 209
TABLE 184 INDIA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION) 209
TABLE 185 INDIA: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 210
TABLE 186 INDIA: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 210
TABLE 187 INDIA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 210
TABLE 188 INDIA: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 211
10.3.10 REST OF ASIA PACIFIC 211
TABLE 189 ROAPAC: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 212
TABLE 190 ROAPAC: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 212
TABLE 191 ROAPAC: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 213
TABLE 192 ROAPAC: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 213
TABLE 193 ROAPAC: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 213
TABLE 194 ROAPAC: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 214
TABLE 195 ROAPAC: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 214
TABLE 196 ROAPAC: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 214
10.4 LATIN AMERICA 215
10.4.1 GROWING CANCER RESEARCH AND MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH 215
TABLE 197 LATIN AMERICA: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040 215
TABLE 198 LATIN AMERICA: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 216
TABLE 199 LATIN AMERICA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION) 216
TABLE 200 LATIN AMERICA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 217
TABLE 201 LATIN AMERICA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION) 217
TABLE 202 LATIN AMERICA: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 217
TABLE 203 LATIN AMERICA: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 218
TABLE 204 LATIN AMERICA: CYTOGENETICS MARKET BY TYPE,
2020–2026 (USD MILLION) 218
TABLE 205 LATIN AMERICA: CYTOGENETICS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 218
10.5 MIDDLE EAST & AFRICA 219
10.5.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH 219
TABLE 206 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION) 220
TABLE 207 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION) 220
TABLE 208 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 221
TABLE 209 MIDDLE EAST & AFRICA: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 221
TABLE 210 MIDDLE EAST & AFRICA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION) 221
TABLE 211 MIDDLE EAST & AFRICA: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 222
TABLE 212 MIDDLE EAST & AFRICA: CYTOGENETICS MARKET BY TYPE,
2020–2026 (USD MILLION) 222
TABLE 213 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION) 222
11 COMPETITIVE LANDSCAPE 223
11.1 OVERVIEW 223
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 223
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE CANCER BIOMARKERS MARKET 224
TABLE 214 STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES 224
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 225
FIGURE 36 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CANCER BIOMARKERS MARKET 225
11.4 MARKET SHARE ANALYSIS 226
TABLE 215 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION 226
11.5 COMPANY EVALUATION QUADRANT 227
11.5.1 STARS 227
11.5.2 EMERGING LEADERS 227
11.5.3 PERVASIVE PLAYERS 227
11.5.4 PARTICIPANTS 228
FIGURE 38 CANCER BIOMARKERS MARKET: COMPANY EVALUATION QUADRANT, 2020 228
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020) 229
11.6.1 PROGRESSIVE COMPANIES 229
11.6.2 STARTING BLOCKS 229
11.6.3 RESPONSIVE COMPANIES 229
11.6.4 DYNAMIC COMPANIES 229
FIGURE 39 CANCER BIOMARKERS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2020 230
11.7 COMPETITIVE BENCHMARKING 230
FIGURE 40 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CANCER BIOMARKERS MARKET 230
TABLE 216 COMPANY PRODUCT FOOTPRINT 231
TABLE 217 COMPANY REGIONAL FOOTPRINT 231
11.8 COMPETITIVE SCENARIO 232
11.8.1 PRODUCT LAUNCHES & APPROVALS 232
TABLE 218 KEY PRODUCT LAUNCHES & APPROVALS 232
11.8.2 DEALS 233
TABLE 219 DEALS 233

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127